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Abstract 
The role of glutamine as a metabolic fuel for the 
starving intestines, its capacity to limit bacterial 
translocation, lung sepsis and a pro-inflammatory cytokine 
response are reviewed in the context of uncertainities 
regarding current recommendations for glutamine 
supplementation in parenterally-fed critically ill patients. 
Weaknesses in the evidence-base showing benefit of 
intravenous glutamine supplementation are discussed 
together with aspects of glutamine supplementation via the 
enteral route. 
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Why glutamine?  
Over the past decade, the amino acid glutamine has 
repeatedly come under the spotlight as one of the 
intravenous nutritional supplements that may rescue 
the critical care patient from developing the systemic 
inflammatory response syndrome (SIRS) and multi-
organ dysfunction syndrome (MODS) 
1
 resulting from 
unrestricted release of proinflammatory cytokines that 
often follows severe sepsis, shock or trauma. 
The candidate molecule for such a rescue operation 
should not only supply the right cellular metabolic 
fuels for the scenario but should also have immuno-
modulating abilities such as the capacity to regulate 
the inflammatory response so that it kills enough 
bacteria without causing fatal damage to the patient’s 
vital organs and their microcirculation.   
The glutamine molecule has some outstanding 
nutritional credentials which should make it eligible 
for this task.  For example, it is the most abundant 
amino acid in the body, it exhibits the highest 
concentration in peripheral blood and (taurine 
excluded) it has the next highest concentration in the 
cytosol in the cells of vital organs. Its five-carbon 
chassis can be oxidized (i.e. burnt) as a metabolic fuel 
or used anabolically as a building block to make other 
amino acids. Glutamine also stands out amongst its 
competitors because it has not one but two nitrogen 
moieties, the α amino group which can carry ammonia 
and the amide group which supplies nitrogen for the 
synthesis of nucleotides in rapidly dividing immune 
cells such as macrophages or lymphocytes. 
 
Glutamine: the key to interorgan nitrogen 
exchange 
Glutamine is the currency responsible for the major 
part of the flux of nitrogen that occurs between organs 
undergoing protein breakdown and those undergoing 
build-up respectively. This ability to shuttle large 
amounts of nitrogen quickly is complemented by 
glutamine’s capacity to regulate the rate of protein 
synthesis. Glutamine can also carry toxic ammonia to 
the kidney where it releases it as a buffer to bind to H
+
 
ions in the urine. Glutamine is both a nitrogen carrier 
and a metabolic fuel. The oxidation of its carbon 
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chassis yields almost as much energy in the form of ATP, 
the energy currency of the cell, as when glucose is 
oxidized (endnote 1).
2
   
 
Muscle glutamine: food for the starving gut 
Most tissues have the faculty to both synthesise and to 
breakdown, and therefore to utilize, glutamine. Muscle and 
brain are the main manufacturers of glutamine while the 
gut is the main consumer. The starving gut uses muscle-
derived glutamine as its main fuel (endnote 2).
3 
 The gut is 
also capable of utilizing glutamine delivered through the 
enteral or parenteral route. The liver can flip from net 
synthesis to net utilisation according to metabolic demands. 
Synthesis involves the addition of ammonia (NH3) to the 
amino acid glutamate while break down releases NH3 from 
glutamine. For obvious reasons the enzymes responsible 
for these two reactions are located in different 
compartments of the cell in order to prevent wasting 
energy through the phenomenon of futile substrate cycling.  
 
 
The post absorptive state: a happy time of glutamine 
balance 
The biggest stores of glutamine occur in skeletal muscle. 
This is not surprising as muscle tissue contains 80% of the 
body’s total amino acids, muscle glutamine concentrations 
being 30 times higher than those of plasma. During the 
postabsorptive state e.g. 6 hours after a meal when neither 
feeding nor fasting are influencing metabolism, muscle 
tissue releases its glutamine stores into the blood for use 
by the intestinal cells or enterocytes as a fuel. Here 
glutamine liberates NH3 and glutamate is oxidised to CO2 
and water via the Krebs cycle to energise gut metabolism.  
Toxic ammonia is produced by the gut as a by-product 
but, unlike in other organs with a systemic drainage, blood 
from the gut returns to the heart via the portal vein and the 
liver. The liver detoxifies NH3 by converting it into urea 
except in liver disease when ammonia escapes into the 
blood and brain causing the syndrome of hepatic 
encephalopathy. In the fed state muscle export of 
glutamine is balanced by gut consumption and plasma 
glutamine  levels are steady.  After a protein meal (meat 
protein contains 50% glutamine) any surplus glutamine 
can be converted to the amino acid alanine and together 
with alanine derived from muscle glutamine, it can be 
metabolised by the liver to produce glucose (Figure 1). 
 
 
The critically ill starving patient: a time of glutamine 
need 
During starvation gut utilisation of glutamine continues, 
muscle glutamine stores becomes depleted, plasma 
glutamine falls and the liver switches to glutamine 
synthesis to try to make up the deficit. Acidosis is common 
during starvation especially in critical illness and this 
unfortunately increases the kidneys’ demand for (and 
utilisation of) glutamine. Replicating immune cells 
place a further new demand on glutamine stores.  
Muscle synthesis of glutamine cannot keep up with 
consumption in gut, kidney, and immune system and 
progressive glutamine depletion sets in (endnote 3).
4
 
 
 
Figure 1: Glutamine metabolism in the post absorptive state. 
 
 
Progressive muscle wasting further depletes muscle 
glutamine reserves. The liver cannot synthesize 
enough glutamine even if the patient is fed with 
intravenous amino acids. Glutamine supplementation 
of parenteral nutrition (PN) corrects much of this 
depletion, improves nitrogen balance and leads to 
desirable clinical benefits. Intravenous infusions of 
free glutamine in critically ill patients at doses up to 
0.86 g/kgBW/day normalized plasma glutamine levels 
but did not affect muscle glutamine concentrations 
(Figure 2).
5
  
 
 
 
Figure 2: Glutamine metabolism during sepsis, starvation 
and acidosis. 
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Glutamine on the ground: how does it work? 
Glutamine attenuates the derangement in physiology of 
many critically ill patients as shown by human, (clinical 
and volunteer) and animal experimental studies (see 
below). A common scenario where glutamine may be of 
benefit is that of a severely burnt ICU patient, suffering 
from septic shock who requires inotropic support. Here gut 
ischaemic injury leads to a number of dangerous sequelae 
(Figure 3) each of which has a potential for correction by 
glutamine. 
 
 
Figure 3: Typical sequelae of gut ischaemia and starvation. 
 
 
Firstly, gut ischaemia releases excess proinflammatory 
cytokines. Glutamine metabolism, through NADPH 
production, increases the ratio of reduced glutathione 
(GSSH) to oxidized glutatathione (GSSG). This redox 
change lowers synthesis of a number of harmful 
proinflammatory cytokines such as TNF through 
regulation of transcription of NF-κB, the nuclear factor 
kappa-light-chain-enhancer of activated B cells.
6
        
 The other way in which glutamine may help is by 
increasing the synthesis of Heat Shock Protein (HSP) 
which acts as a chaperone to nascent polypeptides that are 
otherwise damaged by inflammation. HSP strengthens the 
cytoskeleton of epithelial cells and increases epithelial 
integrity and down regulates the expression of harmful 
cytokines such as interleukin 1 (IL-1), increasing tolerance 
to endotoxaemia.
7
  
Intravenous glutamine enhanced pulmonary HSP 
production, attenuated lung histologic damage and lowered 
indices of lung tissue metabolic function and mortality in a 
rat model of sepsis.
8
  Significant correlations between 
clinical outcome and circulating HSP level augmentation 
have been observed in critically ill patients supplemented 
with intravenous glutamine.
9
  Supplementation of patients 
with multiple trauma and a high injury severity score with 
oral glutamine was associated with a reduced incidence of 
bacteraemia and pneumonia.
10 
 Oral glutamine has also 
been reported to improve intestinal barrier function 
after high dose chemotherapy.
11
   
Secondly, gut ischaemia through the release of Fas 
ligand increases enterocyte apoptosis, which results in 
loss of gut barrier function and more bacterial 
translocation. Here glutamine may increase survival by 
its ability to suppress a number of kinases which 
mediate apoptosis or cell suicide in response to 
binding of ligand to Fas “death receptors.” 12           
Thirdly the inflamed ischaemic gut conditions 
circulating neutrophils to invade the endothelium as 
part of a systemic inflammatory response. Glutamine 
is well placed to reduce neutrophil adhesion to gut 
vascular endothelium and its subsequent migration. 
Hou et al reported reduced vascular CAM-1 
expression on, and leucocyte transmigration through, 
human umbilical vein endothelial cells stimulated by 
arsenic.
13
   
Glutamine has also been shown to improve 
glycaemic control in critical illness which often causes 
insulin insensitivity and obligatory gluconeogenesis. 
Glutamine supplementation decreased insulin 
requirements in critically ill patients requiring TPN.
14
  
Although glutamine is itself a substrate for 
gluconeogenesis it has the incretin potential to increase 
insulin secretion by raising circulating Glucagon-like 
peptide (GLP-1) and glucose dependent insulinotropic 
factor (GIP).
15
  
 
 
Glutamine: can we deliver it? 
The low solubility  of free glutamine (35g/l at 
20ºC), which may drop further after admixture with 
parenteral amino acid solutions, often necessitates 
unwanted bulky additions to the PN regimen. 
Variations in pH and temperature during manufacture 
and storage may promote non enzymatic degradation 
of glutamine to pyroglutamic acid (pGlu and ammonia 
(NH3) which can cause cerebral toxicity. Peter Furst
16
 
pioneered the commercial synthesis of a dipepetide 
containing Alanine-Glutamine (Ala-Glu, Dipeptiven
®
, 
Fresenius Kabi). Ala-Glu is 16 times more soluble 
than free glutamine and is stable with a shelf life of 24 
months when stored below 25ºC. When Ala-Glu was 
infused continuously intravenously into healthy 
volunteers, it was rapidly hydrolised by circulating and 
membrane bound extracellular dipeptidases causing a 
30% rise in plasma free glutamine.
17
 
Dipeptides are stable and do not decompose to 
PGlu or NH3. which could cause cerebral toxicity. Ala-
Glu infusions almost abolished trauma-induced muscle 
glutamine depletion and reversed negative nitrogen 
balance after major surgery.
18
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Urinary and dialysate losses are well balanced by the 
infusion and NH3 derived from glutamine metabolism does 
not reach toxic levels except in patients with severe hepatic 
impairment. Dipeptiven provides 82 g alanine and 135 g 
glutamine per ml.  The maximum daily dose of 2mls/kg 
recommended by the manufacturer would supply 0.27 g 
glutamine/kg BW which is within the ESPEN 
recommended dose range.   
An alternative dipeptide glycyl-glutamine (Gly-Glu, 
Glamine
®
, Fresenius Kabi) is also available as part of a 
complete well balanced aminoacid solution for use in PN 
regimens. A daily infusion of 1 litre Glamin in a 70 kg 
patient would supply 0.32g N/kgBW/day and 0.28g 
glutamine/kgBW/day. 
 
Glutamine: enteral or parenteral?       
Protein-based enteral feeds contain typically 5-8g 
glutamine per 100 g protein. Glutamine enriched enteral 
feeds deliver more glutamine e.g. Reconvan
®
 Fresenius 
Kabi  supplies 18 g glutamine per 100 g protein. Enteral 
glutamine supplementation would supply the preferred 
metabolic fuel to enterocytes and minimise the depletion 
of muscle gut glutamine stores that is required to correct 
the fall in plasma glutamine level induced by critical 
illness. However glutamine absorbtion may be impaired in 
critically Ill patients, e.g. those with intestinal ileus, while 
excess intestinal bacteria may consume significant 
amounts of enterally infused glutamine. Since glutamine is 
mostly absorbed in the upper jejunum it may not reach the 
lower intestine which is better “fed” via the parenteral 
route.  Replenishment of the body glutamine pool is slower 
with the enteral route
16  
and plasma glutamine levels have 
not been shown to normalize consistently after enteral 
glutamine supplementation
19  
as has been observed after 
parenteral glutamine. The carrier for glutamine (free or 
protein bound), the rate and site of enteral infusion (bolus 
or continuous, gastric or intestinal) may alter glutamine 
delivery to the systemic circulation. Only a fraction of 
absorbed glutamine is recovered from portal venous 
blood
20  
which undergoes hepatic first pass elimination 
before it reaches the systemic circulation. Although plasma 
glutamine may not mirror intracellular glutamine stores, 
failure to find reports of normalization of plasma 
glutamine after enteral supplementation suggests that 
enteral glutamine often fails to restore negative glutamine 
balance unless accompanied by parenteral glutamine 
supplementation. This is unfortunate since enteral feeding 
is generally the preferred route of feeding over PN for the 
critically ill patient who requires nutritional support. The 
Canadian 2009 guidelines (see below) state that enteral 
glutamine should be considered in burn and trauma 
patients but there are insufficient data to support the use of 
enteral glutamine in other critically ill patients. 
 
Parenteral glutamine in ITU: who should receive it? 
The American Society of Parenteral and Enteral 
Nutrition (ASPEN) recently published a position 
statement advocating the use of FDA-approved 
parenteral glutamine preparations in critically ill 
postoperative or ventilator-dependent patients. These 
recommendations are based on five meta-analysis of 
46 studies involving 2780 critical care treatments.
21
     
The relative risk (RR) ratios for mortality and 
infections after glutamine supplementation versus 
unsupplemented controls  and their 95% confidence 
intervals are shown in forest plots (Figures 4 and 5) 
calculated using the Comprehensive Meta-analysis 
Package Ver. 2.0.
22
 The size of the square symbols is 
proportional to the weighting given to individual 
studies. The pooled relative risk ratios for mortality 
(0.741) and infection (0.791) significantly favoured 
intravenous glutamine supplementation; the ideal dose 
being estimated as close to 0.5 g glutamine /kgBW/day.             
 
 
 
Figure 4: Forest logarithmic plot of relative risks (RR) of 
death with and without glutamine infusion in critically ill 
patients and associated confidence limits. RR<1 favours 
glutamine, RR> 1 favours no glutamine. Weighting of 
different studies indicated by size of squares. Pooled risk 
ratio of 0.741 and its confidence limit (parallelogram) 
significantly favour glutamine infusion. 
 
 
 
Figure 5: Forest logarithmic plot of relative risks (RR) of 
severe infections with and without glutamine infusion in 
critically ill patients and associated confidence limits. RR<1 
favours glutamine, RR> 1 favours no glutamine. Weighting 
of different studies indicated by size of squares. Pooled risk 
ratio of 0.791 and its confidence limit (parallelogram) 
significantly favour glutamine infusion.  
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The American ASPEN / SCCM 2009 guidelines state 
that when PN is used in a critical care setting consideration 
should be given to parenteral glutamine supplementation.
23
 
The Canadian CCCN 2009 guidelines state that when PN 
is prescribed to critical care patients parenteral glutamine 
supplementation is strongly recommended whereas data 
was insufficient to recommend enteral glutamine 
supplements
24
. The European ESPEN 2009 guidelines 
state that when PN is indicated in intensive care unit 
patients the amino acid solution should contain 0.2 to 0.4 
grams L glutamine /kgBW/day, e.g. 0.3 – 0.6 g/kg/day 
alanyl-glutamine dipeptide.
25
 
The inclusion of critcally ill and / or surgical patients 
makes the ASPEN pool of five meta-analysis heterogenous. 
The study group with the highest weighting (Heyland, 13 
studies) differed from the other four study groups in 
reporting uniformly significant benefit of intravenous 
glutamine. No overall attempt was made to select patients 
who may benefit more from supplementation (e.g. by 
using biomarkers or by selecting low-BMI patients). 
Moreover meta-analysis does not allow for publication 
bias or exclusion of studies not reported in English. 
Despite the positive signal given by the combined meta-
analysis the recommendations need further statistical 
backing.  
Glutamine supplementation of PN did not significantly 
reduce new infection or mortality in the SIGNET
26 
and 
earlier Avenell 
27 
trials (502 and 279 critically–ill patients 
respectively). The findings of the ongoing REDOXS trial
28
 
of combined enteral and parenteral supplementation is 
therefore eagerly awaited.        
  
Conclusion 
Glutamine is a nutritionally non-essential amino acid 
that becomes conditionally essential during critical illness. 
Glutamine released from muscle in large amounts 
(typically eight grams per day) becomes a major metabolic 
fuel in this scenario. Depletion of muscle glutamine stores 
deprives the gut of its prime metabolic fuel. Effective 
repletion of whole body glutamine stores has the potential 
to restore gut barrier function, to reduce lung sepsis and to 
fuel immune cells to modulate the cytokine response to 
injury and sepsis away from the profile associated with 
SIRS / MODS and to normalize REDOX state in vital 
organs. American, European and Canadian guidelines 
recommend parenteral glutamine supplementation in 
critical care patients receiving PN. These 
recommendations need to be strengthened by carefully 
designed clinical trials with specific primary endpoints in 
selected subgroups of critically ill patients receiving PN. 
The therapeutic potential of combinations of glutamine 
with other intravenous immunomodulators (e.g. arginine, 
ω-3 fatty acids) or antioxidants ( e.g. Vitamin E, ascorbic 
acid and in particular selenium) also merit further 
investigation.  
Endnotes 
1.  Metabolism of glutamine to α-ketoglutarate and subsequent 
complete oxidation in the Kreb’s cycle yields 30 moles ATP 
per mole glutamine compared to 36 moles of ATP released by 
the complete oxidation of one mole of glucose.  
2. During starvation glutamine, acetoacetate and 
hydroxybutyrate constitute 35, 24 and 26 percent respectively 
while glucose constitute only 7 percent of the total fuel 
oxidized by the rat intestine. 
3. During postoperative trauma in a 70 kg patient typical daily 
glutamine uptakes by the intestine, kidney, and immune 
system are 10-14 g, 4g, and 2-4 g respectively while daily 
glutamine efflux from muscle is typically 8-10g. This results 
in a daily negative glutamine balance of minus 6 to 14g. 
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